; and (C) supply chains with single points of failure and limited resiliency; (5) legislative, regulatory, and policy changes necessary to avoid, or prepare for, contingencies identified in the report; and (6) recommendations to diversify supply away from complete dependency on sources of supply in competitor countries and politically unstable countries that may cut off United States supply, and address critical bottlenecks and mitigate single points of failure and limited resilience. (c) Preference for medicines (1) In general Except as provided in paragraph (2) and under section 1107a(d) of title 10, United States Code, the Secretary of Defense and the Secretary of Veterans Affairs— (A) may only acquire and purchase American-made and Federal Drug Administration approved raw materials, medicines, and vaccines for the Department of Defense; and (B) shall use the authorities under the Defense Production Act to acquire and purchase such raw materials, medicines, and vaccines, recognizing the national security vulnerabilities of a dependency on a foreign medical supply chain. (2) Exception Paragraph (1) does not apply in any case where the Secretary of Defense determines that a shortage of any raw material, medicine, or vaccine is such that it becomes unavoidable to acquire such raw material, medicine, or vaccine from a trusted foreign supplier. (3) American-made For purposes of this subsection, the term American-made supplied from, created, or supplied by the United States, including any territory or possession of the United States.